What happens when patients stop taking GLP-1 medications? A new Cleveland Clinic study reveals real-world insights
As the use of injectable GLP-1 drugs continues to increase, questions persist about what happens after patients stop taking them in real-world settings. A new Cleveland Clinic analysis of nearly 8,000 patients suggests that, on average, ceasing semaglutide and terzapatide does not lead to significant weight regain in clinical practice, as many patients later resume … Read more
